Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.

about

Isavuconazole shortens the QTc interval.Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Sacubitril/Valsartan (LCZ696) in Heart Failure

P2860

Q47409728-0EEA159A-7B4C-4475-965F-6C1E2E50EB23 Q50634411-491A10C4-4AF3-4215-BF6C-8E5CCFC45CE0 Q57396137-8376C455-FE46-4022-BDF9-FFE7230DA753

P2860

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.

Item

http://www.wikidata.org/entity/Q42424644

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Single therapeutic and suprath ...... affect cardiac repolarization.

@en

Single therapeutic and supratherapeutic doses of sacubitril/valsartan

@nl

type

Item

label

Single therapeutic and suprath ...... affect cardiac repolarization.

@en

Single therapeutic and supratherapeutic doses of sacubitril/valsartan

@nl

prefLabel

Single therapeutic and suprath ...... affect cardiac repolarization.

@en

Single therapeutic and supratherapeutic doses of sacubitril/valsartan

@nl

P1476

Single therapeutic and suprath ...... affect cardiac repolarization.

@en

P2093

Iris Rajman

http://www.w3.org/2001/XMLSchema#string

Jesika Petruck

http://www.w3.org/2001/XMLSchema#string

Kiran Kode

http://www.w3.org/2001/XMLSchema#string

Parasar Pal

http://www.w3.org/2001/XMLSchema#string

Pierre Jordaan

http://www.w3.org/2001/XMLSchema#string

Priya Chandra

http://www.w3.org/2001/XMLSchema#string

Soniya Vaidya

http://www.w3.org/2001/XMLSchema#string

Thomas H Langenickel

http://www.w3.org/2001/XMLSchema#string

P2860

Angiotensin-neprilysin inhibition versus enalapril in heart failure

MERIT-HF mortality and morbidity data.

Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk.

Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.

Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor.

Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.

P2888

s00228-016-2062-9

P304

917-924

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-016-2062-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27083930

http://www.w3.org/2001/XMLSchema#string

P932

4942489

http://www.w3.org/2001/XMLSchema#string

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.

about

P2860

P2860

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932